佰特微医疗完成近亿元B轮融资，发力外周介入与心衰领域产品创新

Core Viewpoint - Shenzhen Baitwei Medical Technology Co., Ltd. has achieved breakthroughs in domestic peripheral vascular intervention devices and completed nearly 100 million RMB in Series B financing to accelerate innovation in the peripheral vascular intervention and heart failure fields [2][4]. Group 1: Product Development and Innovation - Baitwei Medical has established a comprehensive product matrix in the peripheral vascular intervention field, covering "reduction + thrombectomy + access," with several technologies at a leading domestic level [4]. - The company's independently developed peripheral venous thrombectomy system is the only domestic product approved for the "Innovative Medical Device Special Review Green Channel" [4]. - Baitwei Medical is also developing a pulmonary artery thrombectomy system, which is the only self-expanding stent thrombectomy system in China, directly competing with foreign second-generation products [5]. Group 2: Focus on Heart Failure - The company is focusing on heart failure, a critical area in cardiovascular diseases, and aims to develop a comprehensive device solution, particularly targeting the atrial shunt system, to fill a gap in domestic treatment options [10]. - Baitwei Medical is one of the few companies globally to enter the clinical stage for atrial shunt systems, with plans to create the first non-implantable atrial shunt system in the world [10]. Group 3: Strategic Financing and Future Plans - The recent financing round will be used for new product development, construction of production bases, and market expansion, laying a solid foundation for the company's next five years of development [11]. - The company has established a domestic sales headquarters in Beijing, which will support its operational growth [11]. - Investors express confidence in Baitwei Medical's innovative capabilities and its systematic layout in high-potential areas, emphasizing the company's strong research and development transformation capabilities [11].